Journal francais d'ophtalmologie · 2026
Retinal toxicity following SBP-101 combined with gemcitabine and nab-paclitaxel chemotherapy.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Driouich Z, Younis S, Ali A H G
Аннотация
PURPOSE: To report a case of retinal toxicity following the administration of SBP-101 in combination with gemcitabine and nab-paclitaxel chemotherapy in a patient being treated for metastatic pancreatic ductal adenocarcinoma (PDAC).
CASE REPORT: A 59-year-old woman diagnosed with metastatic pancreatic ductal adenocarcinoma was enrolled in a clinical trial involving SBP-101 combined with gemcitabine and nab-paclitaxel. Her ocular examination prior to chemotherapy and during treatment was unremarkable. However, four months after discontinuation of SBP-101, routine ophthalmic screening revealed atrophic changes in the outer retinal layers of both eyes, despite the absence of visual symptoms. The patient was subsequently monitored monthly, with progressive signs of retinal toxicity observed over time.
CONCLUSION: While SBP-101 is under investigation for its potential in treating pancreatic cancer, this case highlights a significant concern regarding its ocular safety profile, particularly in relation to delayed-onset retinal toxicity. This case emphasizes the need for vigilance and long-term monitoring of patients receiving SBP-101-based therapies.
CASE REPORT: A 59-year-old woman diagnosed with metastatic pancreatic ductal adenocarcinoma was enrolled in a clinical trial involving SBP-101 combined with gemcitabine and nab-paclitaxel. Her ocular examination prior to chemotherapy and during treatment was unremarkable. However, four months after discontinuation of SBP-101, routine ophthalmic screening revealed atrophic changes in the outer retinal layers of both eyes, despite the absence of visual symptoms. The patient was subsequently monitored monthly, with progressive signs of retinal toxicity observed over time.
CONCLUSION: While SBP-101 is under investigation for its potential in treating pancreatic cancer, this case highlights a significant concern regarding its ocular safety profile, particularly in relation to delayed-onset retinal toxicity. This case emphasizes the need for vigilance and long-term monitoring of patients receiving SBP-101-based therapies.